<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2013-06-26" updated="2019-12-02">
  <drugbank-id primary="true">DB08913</drugbank-id>
  <drugbank-id>DB05677</drugbank-id>
  <drugbank-id>DB09566</drugbank-id>
  <name>Radium Ra 223 Dichloride</name>
  <description>Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.</description>
  <cas-number>444811-40-9</cas-number>
  <unii>RJ00KV3VTG</unii>
  <average-mass>293.924</average-mass>
  <monoisotopic-mass>292.956202554</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7498</ref-id>
        <pubmed-id>23682134</pubmed-id>
        <citation>Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Kakonen SM, Scholz A: Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst. 2013 Jun 19;105(12):908-16. doi: 10.1093/jnci/djt116. Epub 2013 May 16.</citation>
      </article>
      <article>
        <ref-id>A7499</ref-id>
        <pubmed-id>17544845</pubmed-id>
        <citation>Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587-94.</citation>
      </article>
      <article>
        <ref-id>A7500</ref-id>
        <pubmed-id>17062709</pubmed-id>
        <citation>Bruland OS, Nilsson S, Fisher DR, Larsen RH: High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.&#13;
</indication>
  <pharmacodynamics>Physiologically, Radium Ra 223 Dichloride, prevents the spread of bone cancer by killing the associated bone cancer cells.</pharmacodynamics>
  <mechanism-of-action>Radium Ra 223 Dichloride is the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. The high energy damages bone cells by introducing double-stranded DNA breaks. This leads to cell death and prevention of the spread of the bone cancer cells. As well because of the alpha particle's short range of less than 10 cell diameters, its damaging effects would less likely affect the non-cancerous cells nearby.  &#13;
</mechanism-of-action>
  <toxicity>Because of its cytotoxic actions that have a high potential to cause fetal harm, Radium Ra 223 Dichloride is contraindicated in women who are pregnant or are of child bearing age. Other side effects include several hematological lab abnormalities, peripheral edema, nausea, vomiting, and diarrhea.&#13;
</toxicity>
  <metabolism>Radium-223 does not undergo metabolism because it is a radioisotope that decays.&#13;
</metabolism>
  <absorption>Since Radium Ra 223 Dichloride is administered I.V., the bioavailability should be 100%. </absorption>
  <half-life>The half-life is relatively long at 11.4 days for radium-223.&#13;
</half-life>
  <protein-binding>There is negligible plasma protein binding.</protein-binding>
  <route-of-elimination>Radium-223 is mainly eliminated through the feces (13%) and to a lesser extent in the urine (2%). It is also noted that the elimination rate of radium-223 from the intestines is variable due to the high variability of intestinal transit rates among patients. Therefore there could be more intestinal radiation exposure in patients with slower intestinal transit rates, but the significance of this in relation to toxicity is not known.&#13;
&#13;
</route-of-elimination>
  <volume-of-distribution>The volume of distribution was not quantified, but after 24 hours, there is only 1% radium-223 remaining in the blood. The rest of the radium-223 is distributed to bone (61% of the radioactive dose after 4 hours) and intestine (49% of the radioactive dose after 4 hours). No other organs were found to have significant uptake.</volume-of-distribution>
  <clearance>The clearance rate of radium-223 was not quantified.</clearance>
  <classification>
    <description>This compound belongs to the class of inorganic compounds known as alkaline earth metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a lanthanide.</description>
    <direct-parent>Alkaline earth metal chlorides</direct-parent>
    <kingdom>Inorganic compounds</kingdom>
    <superclass>Mixed metal/non-metal compounds</superclass>
    <class>Alkaline earth metal salts</class>
    <subclass>Alkaline earth metal chlorides</subclass>
    <alternative-parent>Inorganic chloride salts</alternative-parent>
    <substituent>Alkaline earth metal chloride</substituent>
    <substituent>Inorganic chloride salt</substituent>
    <substituent>Inorganic salt</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Radium chloride Ra-223</synonym>
    <synonym language="english" coder="usan">Radium Ra 223 Dichloride</synonym>
    <synonym language="english" coder="">Radium Ra-223 dichloride</synonym>
    <synonym language="english" coder="">Radium-223 chloride</synonym>
    <synonym language="english" coder="">Radium-223 dichloride</synonym>
  </synonyms>
  <products>
    <product>
      <name>Radium Ra 223 Dichloride</name>
      <labeller>Cardinal Health 414, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>65857-906</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>90 uCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA203971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xofigo</name>
      <labeller>Bayer Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002653</ema-product-code>
      <ema-ma-number>EU/1/13/873/001</ema-ma-number>
      <started-marketing-on>2013-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1100 kBq/mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Xofigo</name>
      <labeller>Bayer HealthCare Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50419-208</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>30 uCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA203971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Alpharadin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Radium Ra 223 Dichloride</name>
      <ingredients>Radium Ra 223 Dichloride</ingredients>
    </mixture>
    <mixture>
      <name>Xofigo</name>
      <ingredients>Radium Ra 223 Dichloride</ingredients>
    </mixture>
    <mixture>
      <name>Xofigo</name>
      <ingredients>Radium Ra 223 Dichloride</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Elements</category>
      <mesh-id>D004602</mesh-id>
    </category>
    <category>
      <category>Elements, Radioactive</category>
      <mesh-id>D004603</mesh-id>
    </category>
    <category>
      <category>Isotopes</category>
      <mesh-id>D007554</mesh-id>
    </category>
    <category>
      <category>Metals</category>
      <mesh-id>D008670</mesh-id>
    </category>
    <category>
      <category>Metals, Alkaline Earth</category>
      <mesh-id>D008673</mesh-id>
    </category>
    <category>
      <category>Metals, Heavy</category>
      <mesh-id>D019216</mesh-id>
    </category>
    <category>
      <category>Radioactive alpha-Particle Emitting Therapeutic Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radioisotopes</category>
      <mesh-id>D011868</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>90 uCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>30 uCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1100 kBq/mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB08913.pdf?1372558046</fda-label>
  <patents>
    <patent>
      <number>6635234</number>
      <country>United States</country>
      <approved>2003-10-21</approved>
      <expires>2020-01-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Since radium Ra 223 dichloride is administered intravenously, no food effects should occur.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Radium Ra 223 Dichloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Radium Ra 223 Dichloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Radium Ra 223 Dichloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Radium Ra 223 Dichloride.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.37</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.47e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>dichloro(223Ra)radium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>dichloro(223Ra)radium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>293.924</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>292.956202554</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>Cl[223Ra]Cl</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>Cl2Ra</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>RWRDJVNMSZYMDV-SIUYXFDKSA-L</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>12.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>7.26</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>74895</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175427151</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>28528370</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Radium-223_chloride</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2107816</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/xofigo-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/xofigo.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>